Abbott Laboratories (ABT) Long-Term Debt Repayments (2010 - 2026)

Abbott Laboratories' Long-Term Debt Repayments history runs 15 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, Long-Term Debt Repayments rose 41.46% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $2.9 billion (up 185.9% YoY), while the FY2021 annual figure was $48.0 million, down 96.4% from the prior year.
• Long-Term Debt Repayments came in at $1.4 billion for Q1 2026 at Abbott Laboratories, up from $501.0 million in the prior quarter.
• In the past five years, Long-Term Debt Repayments ranged from a high of $1.4 billion in Q3 2023 to a low of $1.0 million in Q2 2022.
• A 5-year average of $467.2 million and a median of $18.0 million in 2024 frame the typical range for Long-Term Debt Repayments.
• Across the five-year window, Long-Term Debt Repayments surged 144400.0% in 2023 and plunged 99.86% in 2024, its largest moves.
• Abbott Laboratories' Long-Term Debt Repayments stood at $1.0 million in 2022, then soared by 144400.0% to $1.4 billion in 2023, then slumped by 99.86% to $2.0 million in 2024, then surged by 24950.0% to $501.0 million in 2025, then soared by 182.63% to $1.4 billion in 2026.
• According to Business Quant data, Long-Term Debt Repayments over the past three periods registered $1.4 billion, $501.0 million, and $1.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.

Peer Comparison